Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits.

To study the biocompatibility and the biodegradation rate in vivo of new intravitreal implants made with three different hyaluronic acid esters: Hyaff7, Hyaff11 and Hyaff11p75 (100% ethyl ester, 100 and 75% benzyl esters, respectively), the plugs were implanted through a sclerotomy at 3.5 mm from the limbus of rabbit eyes. In order to evaluate the in vivo biodegradation the shaft diameter of the plugs was measured by ultrasound biomicroscopy. Slit lamp microscopy, ophthalmoscopy and ERG were performed periodically. The effects of the implants on ocular tissues were also evaluated histologically. All the plugs showed a good biocompatibilitv. Plugs of both the total esters, Hyaff7 and Hyaff11, were found to undergo a slow dissolution process for 60 and 150 days, respectively. The partial benzyl ester, Hyaff11p75, was completely reabsorbed after 15 days. Analysis of variance showed a high correlation between biodegradation rate and the time of resorption (F = 90.5; p < 0.001). The biodegradation rate of each implant is related to the chemical structure of the three types of Hyaff (F = 4.51; p = 0.005). The present data suggest that intravitreal implants based on hyaluronic acid esters represent useful biocompatible and biodegradable devices for a potential drug delivery system in the treatment of posterior segment ocular diseases.

[1]  D. Williams,et al.  Quantitative assessment of the tissue response to films of hyaluronan derivatives. , 1996, Biomaterials.

[2]  Thomas J. Smith,et al.  Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. , 1992, Archives of ophthalmology.

[3]  S. Cousins,et al.  Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. , 1994, Archives of ophthalmology.

[4]  B. Joondeph,et al.  Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. , 1988, Ophthalmic surgery.

[5]  P. A. Pearson,et al.  An intravitreal device providing sustained release of cyclosporine and dexamethasone. , 1994, Current eye research.

[6]  Y. Ikada,et al.  A new vitreal drug delivery system using an implantable biodegradable polymeric device. , 1994, Investigative ophthalmology & visual science.

[7]  Y Ikada,et al.  Biodegradable scleral implant for intravitreal controlled release of fluconazole. , 1997, Current eye research.

[8]  Y. Ikada,et al.  Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. , 1995, Current eye research.

[9]  G. Peyman,et al.  Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. , 1986, Investigative ophthalmology & visual science.

[10]  R. Cortivo,et al.  In vitro studies on biocompatibility of hyaluronic acid esters. , 1991, Biomaterials.

[11]  M. Davis,et al.  Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant , 1997 .

[12]  C Tello,et al.  Measurement of ultrasound biomicroscopy images: intraobserver and interobserver reliability. , 1994, Investigative ophthalmology & visual science.

[13]  M Moras,et al.  Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. , 1993, Biomaterials.

[14]  D. Williams,et al.  Biodegradation of hyaluronic acid derivatives by hyaluronidase. , 1994, Biomaterials.

[15]  Y. Ikada,et al.  Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. , 1992, Investigative ophthalmology & visual science.

[16]  Y. Ikada,et al.  Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. , 1997, Current eye research.

[17]  A. Urtti,et al.  Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies , 1992 .